Table 1.
Baseline characteristics and demographics.
| Stratified |
|||
|---|---|---|---|
| Total cohort | Non-daily headache | Dailyheadache | |
| n = 25 | n = 16 | n = 9 | |
| Characteristics | |||
| Age in years, mean (SD) | 46.5 (10.1) | 47.4 (11.5) | 44.8 (7.2) |
| Female, n (%) | 17 (68) | 12 (75) | 5 (56) |
| Chronic migraine, n (%) | 22 (88) | 14 (88) | 9 (100) |
| Aura, n (%) | 12 (48) | 6 (38) | 6 (67) |
| Migraine years, mean (SD) | 25.7 (10.3) | 29.9 (9.3) | 19.2 (8.5) |
| First monoclonal antibody | |||
| Erenumab, n (%) | 25 (100) | 16 (100) | 9 (100) |
| Started with initial dose of 70 mg, n (%) | 25 (100) | 16 (100) | 9 (100) |
| Increased dose to 140 mg, n (%) | 23 (92) | 15 (94) | 8 (89) |
| Baseline headache days, mean (SD) | 21.1 (6.7) | 17.2 (5.3) | 28 (0.0) |
| Baseline acute medication days, mean (SD) | 8.5 (3.0) | 8.8 (3.0) | 8.1 (3.2) |
| № of patients with MO at baseline, n (%)a | 6 (24) | 4 (25) | 2 (22) |
| Concomitant prophylaxis, n (%) | 7 (28) | 2 (13) | 5 (56) |
| Break | |||
| Mean duration break in days, mean (SD)b | 93.4 (55.9) | 87.4 (44.1) | 104.1 (74.3) |
| Concomitant prophylaxis, n (%) | 6 (24) | 2 (13) | 4 (44) |
| Second monoclonal antibody | |||
| Galcanezumab, n (%) | 12 (48) | 7 (44) | 5 (56) |
| Fremanezumab, n (%) | 13 (52) | 9 (56) | 4 (44) |
| Baseline headache days, mean (SD) | 20.8 (7.1) | 17.1 (6.1) | 27.6 (1.3) |
| Baseline acute medication days, mean (SD) | 9.1 (4.7) | 9.2 (4.6) | 9.0 (5.3) |
| № of patients with MO at baseline, n (%)a | 7 (28) | 4 (25) | 3 (33) |
| Concomitant prophylaxis, n (%) | 6 (24) | 2 (13) | 4 (44) |
SD = standard deviation; mAb = monoclonal antibody; MO = medication overuse.
aMO defined as: intake of any combination of ergotamine, triptans, non-opioid analgesics and/or opioids on a total of ≥10 days/month.
bDuration in days between the last injection of the first monoclonal antibody and the first injection of the second monoclonal antibody.